The BCI Priority Setting Partnership is a collaborative process to identify and prioritise the Top 10 priorities for future brain-computer interface (BCI) research. The partnership brings together patients, carers, clinicians, and academics, with a particular focus on motor impairments caused by motor neurone disease, stroke, and spinal cord injury.

The partnership is funded by the UK Advanced Research and Invention Agency (ARIA), and supported by the non-profit initiative, the James Lind Alliance. Since 2004, Priority Setting Partnerships have successfully identified research priorities for over 165 conditions and/or therapies. This has helped to inform funding priorities, ensured more time is spent on high priority research activities, and enabled the patient voice to directly influence research agendas.

Supported by:
James Lind Alliance MND Association Stroke Association ARIA

What does the priority setting process look like?

Establishing the partnership

Establishing the partnership

We will form a Steering Group, bringing together people with motor neurone disease, stroke, spinal cord injury, their carers, clinicians, and academics. They agree on the scope of the partnership, what will happen and when, and who else to work with in order to reach as wide an audience as possible.

You tell us the questions you think research should answer

You tell us the questions you think research should answer

We will ask people with motor impairments, carers, clinicians, and the wider BCI community to tell us what questions they think research should answer.

Data processing

Data processing

We will collect all the questions and sort them into themes. We will also look to see whether any of the questions have been answered by research already.

First round of priority setting

First round of priority setting

We will ask people with motor impairments, carers, clinicians, and the wider BCI community to look at the long list of questions and choose their top 10. From this, we can develop a shortlist of questions.

Final round of priority setting

Final round of priority setting

We will hold a workshop, involving all stakeholders, to look at the shortlist of questions and come to a consensus on the final Top 10.


What is a BCI?

According to the US Food and Drug Administration, an implanted BCI is a neuroprosthesis that interfaces with the central or peripheral nervous system to restore lost motor and/or sensory capabilities in patients with paralysis or amputation.

Explore the Top 10

Work in progress... The partnership is currently working to develop the consensus list of Top 10 research priorities.

Who Are We?

Team Members

Mr Akram is a consultant neurosurgeon at the National Hospital for Neurology and Neurosurgery (UCLH) and the Unit of Functional Neurosurgery (UCL) in Queen Square.

Indivdual with lived experience.

Family member/carer of an individual with lived experience.

Dr Luke Bashford specialises in human Neuroscience and Neurotechnology. Luke leads academic clinical trials for human implanted Brain-Computer Interfaces and other implanted neurotechnologies in the UK and USA. His research group uses the recording and stimulation capabilities of these devices to investigate the neural mechanisms underlying human cognitive and sensorimotor function for basic science and clinical translation for neurological disorders. In the broader community, he sits on national and international committees and consortia for brain-computer interfaces such as the International BCI Society and iBCI-CC. He works directly with PPIE partners and advises government, industry and third sector organisations. Luke co-leads the National Consortium for Neurotechnology Regulation, a UK Centre of Excellence in Regulatory Science and Innovation.

Qualified and practicing Speech and Language Therapist (SLT) and Research Fellow at UCL's Global Disability Innovation Hub (GDI Hub), and co-Director of GDI Hub's newly launched Centre for Digital Language Inclusion. Principal SLT with the MND Association, the leading non-profit/charity for people living with motor neurone disease (MND) in the UK.

To be completed.

To be completed.

Individual with lived exprience.

Family member/carer of individual with lived experience.

Individual with lived experience.

Hugo is a neurosurgery registrar at the National Hospital for Neurology and Neurosurgery, Queen Square, and currently a Doctoral Clinical Fellow at UCL/The Francis Crick Institute where his PhD is in Neuroscience and Neurotechnology. His research focuses on using novel electrodes (Neuropixels) to understand how individual neurons function in the human brain in different disease states.

Individual with lived experience.

Family member/carer of individual with lived experience.

Physiotherapist and Postdoc Research Fellow in the Abilities Research Center, Icahn School of Medicine at Mount Sinai.

Professor of Clinical Neurology and Honorary Consultant Neurologist at the Stroke Research Centre, UCL Institute of Neurology, Queen Square, and the National Hospital for Neurology and Neurosurgery (NHNN), University College Hospitals (UCH) NHS Foundation Trust. He trained in medicine at Guy's hospital and in neurology at Kings College Hospital, St Thomas' hospital and the National hospital, Queen Square. Professor Werring contributes to delivering hyperacute and acute stroke care, and runs a specialist clinical service and research program in intracerebral haemorrhage and cerebral small vessel disease. He is Head of the Research Department of Brain Repair and Rehabilitation at the Institute of Neurology, Chair of the Association of British Neurologists Stroke Advisory Group, Stroke Specialty Lead for the NIHR North Thames Clinical Research Network, Expert Advisor to the NICE centre for guidelines, and on the Editorial Boards of the European Journal of Neurology, European Stroke Journal, and Practical Neurology. David was a Visiting Fellow at Clare Hall, University of Cambridge in 2023, and is now a Clare Hall Life Member. David is Past-Chair of the UK Stroke Forum, the largest multidisciplinary event for stroke care professionals in the UK, and is President of the British Association of Stroke Physicians, 2024-2026. He was appointed as an NIHR Senior Investigator in 2024.

PSP Leads

Dr Jamie Brannigan is a clinician scientist who trained at the University of Cambridge, where he also completed an undergraduate degree in neuroscience. He is currently a clinician scientist at Oxford University. His primary research interests are the clinical translation of implantable brain-computer interfaces, and the development of novel endovascular approaches to BCI. Jamie has several years of BCI experience within both academia and industry. In addition to his role at Oxford, he holds an honorary research fellowship at UCL, collaborating on studies aimed at assessing the clinical needs and patient preferences for implantable BCI devices.

Consultant neurosurgeon at the National Hospital for Neurology and Neurosurgery (NHNN). His research interests are in the application of new technologies to improve patient outcomes. Alongside his clinical practice he works with the Sensory Circuits and Neurotechnology laboratory at the Francis Crick Institute on novel neural interfaces and is Chief or Principal Investigator on several clinical trials.

JLA Advisor

To be completed.